Publication | Closed Access

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Hematological MalignancyMedicineMalignant Blood DisorderImmunologyTumor ImmunityImmune SurveillanceImmunotherapeuticsImmunotherapyOncologyRadiation OncologyRefractory Multiple Myeloma